SG 239
Alternative Names: SG-239Latest Information Update: 28 May 2025
At a glance
- Originator Sana Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (IV)
- 30 Apr 2021 Sana Biotechnology plans to file an IND application with the US FDA for SG 239 in Multiple myeloma, in 2022
- 30 Apr 2021 SG 239 is available for licensing as of 30 Apr 2021. https://www.sec.gov/Archives/edgar/data/0001770121/000119312521007483/d60414ds1.htm